Quick summary: what “mots c dosage” usually means
MOTS-c is a 16–amino acid mitochondrial-derived peptide explored for metabolic, exercise and longevity-related research questions. There is no universally accepted medical dose for humans. Figures you see online typically come from non-medical forums or vendor pages and can vary widely.
- Form most often discussed: subcutaneous injection from a lyophilised vial after reconstitution
- Common claim patterns: weekly totals of 5–30 mg split into 1–3 doses over 2–8 weeks
- Evidence status: limited human data; mostly animal or cell studies
- Australian access: unapproved; legal access generally requires medical oversight. See Is MOTS-c Legal in Australia?
MOTS-c product forms people encounter
The term “mots c dosage” spans different product types. Dose depends heavily on what you’re looking at.
- Injectable (most common online): sterile, lyophilised powder reconstituted with bacteriostatic saline, then administered subcutaneously. Vial sizes often labelled as 5 mg or 10 mg.
- Oral capsules: advertised by some vendors; human bioavailability and efficacy are unclear.
- Nasal sprays: occasionally marketed; evidence and standardisation are limited.
Because purity, strength and stability can vary across sources, any discussion of dose must first confirm the exact product, stated vial strength, and laboratory testing. See our Peptide Dosage Guide for why product form and strength matter.
Non-clinical protocol claims commonly referenced
The following ranges reflect what is commonly cited on forums and vendor pages. These are not medical recommendations and are not a substitute for clinical care.
- General or “wellness” cycles: totals of 5–20 mg per week, divided into 1–3 subcutaneous injections, over 4–8 weeks.
- Exercise/endurance-focused claims: 5–10 mg timed 30–60 minutes before training, 1–3 times per week, over 2–6 weeks.
- “Loading then maintenance” patterns: e.g., 10 mg 2–3 times weekly for 2 weeks, then 5–10 mg weekly for another 4–6 weeks.
- Cycle breaks: 4–8 weeks off is often mentioned before repeating a block.
Why the variance? Products, purity, individual goals and tolerability differ. Some clinics running pilot programs report starting far lower (e.g., 2.5–5 mg once or twice weekly) and titrating with close monitoring.
What can influence MOTS-c dose decisions
- Confirmed vial strength and purity: 5 mg vs 10 mg vials change the volume needed after reconstitution.
- Health status and medications: MOTS-c is explored for metabolic effects; those on glucose-lowering therapy may require extra caution.
- Goal and timing: pre-training vs general blocks, and whether you’re cycling alongside deloads.
- Body weight and age: sometimes considered in dose titration, but no validated human algorithm exists.
- Tolerability: clinicians may start low and adjust if side effects occur.
If you see “mcg” and “mg” used interchangeably online, step back and confirm units. A 1,000x error is possible if units are misread.
Administration basics and technique
When people talk about “mots c dosage,” they often mean subcutaneous injection after reconstituting a lyophilised vial. Technique, hygiene and measurement accuracy are critical. If you are not medically trained, do not attempt this without instruction.
- Use clinically appropriate supplies and aseptic technique.
- Confirm reconstitution volume and resulting concentration (mg per mL) before calculating any dose in mL.
- Rotate injection sites and monitor for local reactions.
For step-by-step fundamentals, see our Peptide Injection Guide.
Safety questions and when to seek help
Human safety data for MOTS-c are limited. Reported or plausible reactions include:
- Injection-site redness, swelling or irritation
- Headache, nausea, light-headedness, fatigue
- Changes in glucose handling (e.g., lower readings), especially if using other glucose-lowering agents
Caution is generally advised for people who are pregnant or breastfeeding, under 18, have active cancer or recent cancer treatment, significant liver/kidney/cardiovascular disease, or are on multiple medicines affecting glucose or blood pressure. Stop and seek medical care if you notice allergic-type symptoms, severe dizziness, chest pain, shortness of breath, or signs of infection at the injection site.
For broader context, see the MOTS-c Side Effects page and the cross-compound Peptide Side Effects Guide.
Australian access and legal notes
MOTS-c is not approved by the TGA for general therapeutic use. Access, compounding and supply sit within strict rules, and advertising therapeutic claims is restricted. Importing products or buying from grey-market vendors risks seizure and safety concerns. A lawful pathway typically involves an Australian-registered prescriber and a compliant pharmacy, if appropriate for your case.
Read more: Is MOTS-c Legal in Australia?, Buy MOTS-c Australia, MOTS-c Prescription Australia.
How clinicians may approach dosing in practice
- Assessment first: goals, history, medications, and baseline labs where relevant.
- Start low, adjust slowly: conservative initiation (e.g., 2.5–5 mg once or twice weekly) with symptom and metric tracking.
- Defined stop rules: side effects, lab changes, or lack of benefit at a predefined review point.
- Cycle planning: clear on/off periods with follow-up.
- Documentation: batch, strength, reconstitution math and injection logs to reduce dosing errors.
Related reading in the MOTS-c series
Frequently asked questions about MOTS-c dosage
Is there a standard MOTS-c dose?
No. There is no established human dosing standard. Most numbers online are anecdotal or vendor-supplied. Discuss risks and uncertainties with a clinician.
How do people usually measure a dose from a vial?
They reconstitute a labelled amount (e.g., 10 mg) with a known volume (e.g., 2 mL), then calculate a concentration (e.g., 5 mg/mL) to draw the intended amount. Errors are common without training. See the Peptide Injection Guide.
Daily vs weekly MOTS-c dosing — which is better?
There is no proven “better.” Online claims show weekly totals split into 1–3 injections, and some pre-workout timing. Clinicians may prefer conservative, intermittent schedules with monitoring.
How long before workouts do people take it?
Exercise-focused claims often mention 30–60 minutes pre-session. This is not validated by robust human studies.
Can MOTS-c be combined with other peptides?
“Stacks” appear online, but safety and interactions are unclear. Combining unapproved products can compound risk. Medical advice is recommended.
Who should avoid MOTS-c?
People who are pregnant or breastfeeding, under 18, with active cancer, or on glucose-lowering medicines should avoid unsupervised use and seek medical advice.
How quickly might effects be noticed?
Timelines vary widely in anecdotes. See MOTS-c Results Timeline for what people commonly report vs where evidence exists.
Have questions about MOTS-c dosage? Get help
Share a few details below and a team member will reply with information to discuss with your healthcare provider. We do not send marketing emails.
If you prefer, you can email us via the contact page.
Key takeaways
- There is no standardised human MOTS-c dose; most numbers online are non-clinical claims.
- Dose depends on confirmed vial strength, product quality, goals and tolerability.
- Safety and legality matter: discuss with an Australian-registered clinician before considering use.